Immunoglobulin Replacement Therapy for Primary Immunodeficiencies
Authors:
- 1 July 2014
- journal article
- review article
- Published by Taylor & Francis in Immunotherapy
- Vol. 6 (7) , 853-869
Abstract
Exogenous antibody therapy to protect patients against infections and toxins is over 100 years old, yet progress continues to be made in the manufacture, administration and application of this type of immunotherapy, known as therapeutic human immunoglobulin. For the majority of patients with primary immunodeficiencies, immunoglobulin replacement is the only life-saving therapy and treatment is life-long, since the vast majority of primary immunodeficiency patients have primary antibody failure. Successful treatment depends on multiple factors: the availability of products, the type of immunodeficiency and any comorbidities of the individual patient. Essential components include long-term follow-up, regular monitoring and a close relationship between the patient and the multidisciplinary clinical immunology team. In this article, we describe the current immunoglobulin products and the types of adverse reactions. We provide evidence for clinical decision-making regarding dosing, route of administration and location of therapy, highlighting current 'best practice' recommendations.Keywords
This publication has 54 references indexed in Scilit:
- Intravenous immunoglobulin expands regulatory T cells via induction of cyclooxygenase-2–dependent prostaglandin E2 in human dendritic cellsBlood, 2013
- Subcutaneous Immunoglobulin for Primary and Secondary Immunodeficiencies: an Evidence-Based ReviewDrugs, 2013
- Review of intravenous immunoglobulin replacement therapy trials for primary humoral immunodeficiency patientsInfection, 2012
- Immunoglobulin replacement therapy: Is there a role for IgA and IgM?Journal of Allergy and Clinical Immunology, 2012
- Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapyClinical and Experimental Immunology, 2012
- Bringing immunoglobulin knowledge up to date: how should we treat today?Clinical and Experimental Immunology, 2011
- Key aspects for successful immunoglobulin therapy of primary immunodeficienciesClinical and Experimental Immunology, 2011
- ImmunodeficienciesClinical and Experimental Immunology, 2009
- Rapid subcutaneous immunoglobulin administration every second week results in high and stable serum immunoglobulin G levels in patients with primary antibody deficienciesClinical and Experimental Immunology, 2008
- Preparation and Properties of Serum and Plasma Proteins. IV. A System for the Separation into Fractions of the Protein and Lipoprotein Components of Biological Tissues and Fluids1a,b,c,dJournal of the American Chemical Society, 1946